TheraSkin® Real Human Skin for Treatment of Chronic Wounds Now available through Premier Contract

NEWPORT NEWS, Va., June 19, 2017

A key factor in selecting the appropriate treatment for advanced wound therapy is the total value it provides the patient – specifically, faster healing with as few applications as possible. TheraSkin provides all the relevant characteristics to heal a wound, because it is real skin.  Backed by evidence supporting reduced time to heal with few applications, TheraSkin is an excellent option for patients and clinicians who are interested in a safe, effective and timely healing for their wounds. 

"TheraSkin provides a powerful treatment option at an attractive price point for our customers.  With the signing of this agreement, we are thrilled to provide our clinical and economic solution to Premier's vast partnership of healthcare providers. We are confident that TheraSkin will be a trusted choice for clinicians and patients looking to heal their wounds in a timely fashion and at a reasonable cost," states Allan Staley, CEO, Soluble Systems, LLC.

TheraSkin is one of the fastest growing products in the advanced wound care market. A retrospective clinical study of 188 consecutive patients published in Foot & Ankle Specialist demonstrated healing rates of 60% at 12 weeks for both Diabetic Foot Ulcers (DFU) and Venous Leg Ulcers (VLU) evaluated in the study. ⁽¹⁾

About TheraSkin: TheraSkin is a biologically active, cryopreserved human skin allograft for chronic wounds.  It can be used head-to-toe and has a fully developed extracellular matrix (ECM) with living cells and an "at ready" supply of human growth factors, cytokines and collagen to jumpstart the wound healing process.